Pharmaceutical major Lupin has acquired Netherlands-based Nanomi B.V. With this acquisition, the company has made its foray into the technology intensive complex injectables space.
Nanomi has patented technology platforms to develop complex injectable products. Nanomi has a rich talent pool of scientists who would be backed by Lupin’s global R&D and manufacturing teams.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The company reported 18.97% rise in its net profit at Rs 533.38 crore for the quarter as compared to Rs 448.30 crore for the same quarter in the previous year.
